INTRODUCTION: Some patients with advanced NSCLC show prolonged disease
stabilization on treatment with an EGFR-tyrosine kinase inhibitor (TKI) such as erlotinib. It is …

Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …

Backgrounds Efficacy of gefitinib therapy strongly depends on epidermal growth factor
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …

BACKGROUND: Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor
(EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an …

Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …

Introduction Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the
preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR …

Abstract Objective The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …

Aims: We evaluated the efficacy and safety of erlotinib, and patient characteristics affecting
progression-free survival (PFS), by analyzing data from two Phase II studies of first-line …

Abstract Background In Japan, the clinical efficacy of erlotinib monotherapy in epidermal
growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was …

Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …